Drug Profile
Research programme: cyclin dependent kinase inhibitors - Quest PharmaTech
Alternative Names: 2127 (CDK immunomodulator) - Quest PharmaTech; ACP-2127Latest Information Update: 03 Dec 2018
Price :
$50
*
At a glance
- Originator Quest PharmaTech
- Class Antineoplastics; Macrolides
- Mechanism of Action Cyclin-dependent kinase inhibitors; MTOR protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Preclinical Cancer
Most Recent Events
- 29 Nov 2018 OncoCare Therapeutics in-licenses Targeted Cancer Therapy Technology from Quest PharmaTech for USA
- 16 Mar 2018 Preclinical trials in Cancer in Canada (unspecified route) (Quest PharmaTech pipeline, March 2018)
- 30 Jul 2013 Discontinued - Preclinical for Cancer in Canada (unspecified route) before 2013